Table 1 Basic characteristics and survival analysis of young Chinese lung adenocarcinoma patients
From: The role of CD28 in the prognosis of young lung adenocarcinoma patients
Variables | Group | Total (N = 71) Patient(%) | Stable disease(N = 53) | Progression disease (N = 18) | Univariate analysis | Multivariate analysis |
|---|---|---|---|---|---|---|
age | > 45 | 0 (0) | 0 | 0 | NA | NA |
<=45 | 71 (100) | 53 | 18 | |||
gender | male | 17 (23.94) | 12 | 5 | NA | NA |
female | 54 (76.06) | 41 | 13 | |||
pathology type | adenocarcinoma | 71 (100) | 53 | 18 | NA | NA |
other | 0 (0) | 0 | 0 | |||
TNM stage | I-II | 46 (64.79) | 41 | 5 | < 0.0001 | 0.017 |
III | 25 (35.21) | 12 | 13 | |||
EGFR or ALK mutation | EGFR Exon 19 del | 22 (30.99) | ||||
EGFR Exon 21 L858R | 16 (22.54) | |||||
EGFR Exon 21L861Q | 2 (2.82) | |||||
EGFR Exon 18 G719 | 3 (4.23) | |||||
ALK-EML4 | 10 (14.08) | |||||
mutated | 52 (73.24) | 38 | 14 | 0.607 | 0.143 | |
wild type | 19 (26.76) | 15 | 4 | (EGFR:0.522; ALK:0.802) | ||
smoking history | smoker | 7 (9.86) | 4 | 3 | 0.354 | 0.247 |
non-smoker | 64 (90.14) | 49 | 15 | |||
CD28 status | low expression | 60 (84.51) | 52 | 8 | < 0.0001 | 0.063 |
high expression | 11 (15.49) | 1 | 10 | |||
PD-L1 status | low expression | 19 (26.76) | 18 | 1 | 0.0382 | 0.116 |
high expression | 52 (73.24) | 35 | 17 | |||
PD-1 status | low expression | 38 (53.52) | 31 | 7 | 0.3712 | 0.492 |
high expression | 33 (46.48) | 22 | 11 | |||
CD3 status | low expression | 26 (36.62) | 11 | 15 | < 0.0001 | 0.001 |
high expression | 45 (63.38) | 42 | 3 | |||
CD8 status | low expression | 19 (26.76) | 11 | 8 | 0.0105 | 0.765 |
high expression | 52 (73.24) | 42 | 10 |